VolitionRx Limited
$2.49+5.96%(+$0.14)
TickerSpark Score
54/100
40
Valuation
60
Profitability
100
Growth
40
Health
30
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VNRX research report →
52-Week Range3% of range
Low $1.91
Current $2.49
High $18.80
Companywww.volition.com
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu. Q that detect cancer; Nu.
- CEO
- Cameron Reynolds
- IPO
- 2012
- Employees
- 85
- HQ
- Henderson, TX, US
Price Chart
-74.64% · this period
Valuation
- Market Cap
- $13.32M
- P/E
- -0.70
- P/S
- 5.40
- P/B
- -0.54
- EV/EBITDA
- -1.11
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 89.68%
- Op Margin
- -870.98%
- Net Margin
- -997.46%
- ROE
- 74.16%
- ROIC
- -64495.48%
Growth & Income
- Revenue
- $1.73M · 40.04%
- Net Income
- $-23,357,027 · 13.39%
- EPS
- $-4.40 · 29.03%
- Op Income
- $-21,222,056
- FCF YoY
- 25.29%
Performance & Tape
- 52W High
- $18.80
- 52W Low
- $1.91
- 50D MA
- $3.20
- 200D MA
- $7.02
- Beta
- 1.03
- Avg Volume
- 622.60K
Get TickerSpark's AI analysis on VNRX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 17, 26 | Forterre Gael | other | 5,251 |
| Mar 17, 26 | Rootsaert Rodney Gerard | other | 3,948 |
| Mar 17, 26 | Micallef Jacob Vincent | other | 5,310 |
| Mar 17, 26 | Plummer Nicholas | other | 7,003 |
| Mar 1, 26 | Rootsaert Rodney Gerard | other | 3,321 |
| Mar 1, 26 | Forterre Gael | other | 2,283 |
| Mar 1, 26 | Plummer Nicholas | other | 5,867 |
| Feb 26, 26 | Forterre Gael | other | 149,000 |
| Feb 26, 26 | Rubin Ethel | other | 178,000 |
| Feb 26, 26 | Reynolds Cameron John | other | 486,000 |
Our VNRX Coverage
We haven't published any research on VNRX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VNRX Report →